ANVS · Annovis Bio, Inc.
Annovis Bio Inc (ANVS)
What's happening
- ANVS is up 1.69% today, trading at $1.01. — Live quote
- It's trading within 3% of its 52-week low ($0.95). (Finnhub fundamentals)
- Volume today (5,775) is well below its 3-month average of 877,410. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.40 actual vs. $-0.46 estimated (+13.5%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-10-01 (10 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $68.2M | $62.0M | $40.4M | $42.2M | $25.8M |
| P/E | -1.48 | -1.69 | -1.28 | -1.43 | -1.06 |
| Price/Book | -16.02 | 19.85 | 3.07 | 2.30 | 1.07 |
| ROE | 1079.06% | -1171.64% | -240.63% | -160.48% | -100.87% |
| ROA | -208.33% | -225.48% | -184.18% | -137.11% | -90.75% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-10-20; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Trailing 52-week price return is -52.7%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on ANVS
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0 | — | — | $0 | — | — | $0 |
| Operating income | -$14.4M | -$18.0M | -$7.4M | -$6.3M | -$6.3M | -$4.4M | -$7.8M | -$7.8M |
| Net income | -$14.8M | -$17.6M | -$7.3M | -$6.2M | -$5.5M | -$12.6M | -$5.0M | -$1.1M |
| EPS (diluted) | $-0.40 | $-0.63 | $-0.37 | $-0.32 | $-0.32 | $-0.97 | $-0.44 | $-0.72 |
| EPS (basic) | $-0.40 | $-0.63 | $-0.37 | $-0.32 | $-0.32 | $-0.97 | $-0.44 | $-0.10 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $22.0M | $16.2M | $21.1M | $17.2M | $21.5M | $26.7M | $13.9M | $14.4M |
| Total liabilities | $26.3M | $13.1M | $4.2M | $4.0M | $3.1M | $2.7M | $4.6M | $7.3M |
| Stockholders' equity | -$4.3M | $3.1M | $16.9M | $13.2M | $18.3M | $24.1M | $9.3M | $7.1M |
| Total current assets | — | — | — | — | — | — | — | — |
| Total current liabilities | $6.4M | $12.8M | $3.6M | $3.7M | $2.8M | $2.5M | $3.9M | $5.4M |
| Cash & equivalents | $18.7M | $14.2M | $19.5M | $15.3M | $17.1M | $22.2M | $10.6M | $12.6M |
| Other current assets | — | — | — | — | — | — | — | — |
| Accounts payable | $3.3M | $5.3M | $2.6M | $2.1M | $974.3K | $1.4M | $2.3M | $4.1M |
| Common stock & paid-in capital | $4.3K | $2.9K | $2.7K | $2.0K | $1.9K | $1.9K | $1.4K | $1.3K |
| Retained earnings | -$196.1M | -$181.3M | -$163.7M | -$153.9M | -$146.6M | -$140.4M | -$134.8M | -$129.0M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$21.9M | -$9.0M | -$8.9M | -$3.5M | -$5.1M | -$8.1M | -$8.3M | -$3.2M |
| Financing cash flow | $26.4M | $3.7M | $13.2M | $1.6M | $0 | $19.8M | $6.2M | $11.8M |
| Share-based compensation | $1.6M | $182.8K | $356.5K | $444.6K | $496.6K | $499.9K | $1.5M | $393.1K |
| Change in accounts payable | -$1.9M | $2.7M | $478.5K | $1.1M | -$395.9K | -$935.8K | -$1.8M | $704.8K |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$29.7M | -$26.7M | -$45.0M | -$25.5M | -$14.5M |
| Net income | -$28.9M | -$24.6M | -$56.2M | -$25.3M | -$14.5M |
| EPS (diluted) | $-1.40 | $-2.31 | $-6.23 | $-3.10 | $-1.90 |
| EPS (basic) | $-1.40 | $-2.02 | $-6.23 | $-3.10 | $-1.90 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Sep '22 |
|---|---|---|---|---|---|
| Total assets | $21.1M | $13.9M | $10.2M | $36.0M | $37.1M |
| Total liabilities | $4.2M | $4.6M | $18.0M | $7.7M | $2.5M |
| Stockholders' equity | $16.9M | $9.3M | -$7.8M | $28.3M | $34.6M |
| Total current assets | — | — | $10.2M | $36.0M | $37.1M |
| Total current liabilities | $3.6M | $3.9M | $4.3M | $7.7M | $2.5M |
| Cash & equivalents | $19.5M | $10.6M | $5.8M | $28.4M | $32.0M |
| Accounts payable | $2.6M | $2.3M | $1.3M | $4.0M | $1.8M |
| Common stock & paid-in capital | $2.7K | $1.4K | $1.1K | $816 | $816 |
| Retained earnings | -$163.7M | -$134.8M | -$110.3M | -$54.1M | -$46.3M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$25.6M | -$21.9M | -$40.0M | -$17.3M | -$9.1M |
| Financing cash flow | $34.6M | $26.7M | $17.3M | $4.6K | $46.7M |
| Share-based compensation | $1.8M | $3.8M | $4.6M | $9.2M | $4.7M |
| Change in accounts payable | $284.5K | $1.0M | -$2.7M | $3.3M | $346.2K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding ANVS as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2023-11-20 to 2026-05-20
Recent transactions
- Insiders have net bought 76,344 shares over the last 182 days, across 3 purchases and 0 sales.
- Most recent: Hoffman Michael B (Director) — Open market purchase of 2,562 shares on 2026-05-20.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Hoffman Michael B | Director | Open market purchase | 2026-05-20 | 2,562 |
| Maccecchini Maria-Luisa | President & CEO | Open market purchase | 2025-10-28 | 97,561 |
| Bruck Claudine | Director | Option exercise | 2025-09-10 | 7,142 |
| Walsh Andrew | Vice President, Finance | Grant / award | 2025-06-16 | 500 |
| McCarthy Reid | Director | Grant / award | 2025-06-10 | 2,000 |
| White Mark K. | Director | Grant / award | 2023-11-20 | 2,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-05-20 | Hoffman Michael B | Director | Open market purchase | 2,562 | $1.75 |
| 2026-05-20 | Hoffman Michael B | Director | Open market purchase | 18,849 | $1.80 |
| 2026-05-20 | Hoffman Michael B | Director | Open market purchase | 54,933 | $1.90 |
| 2026-04-02 | Hoffman Michael B | Director | Open market purchase | 713,800 | $2.10 |
| 2025-12-08 | Hoffman Michael B | Director | Open market purchase | 30,000 | $4.34 |
| 2025-12-08 | Hoffman Michael B | Director | Open market purchase | 15,000 | $4.24 |
| 2025-11-24 | Hoffman Michael B | Director | Open market purchase | 1,489 | $4.13 |
| 2025-11-24 | Hoffman Michael B | Director | Open market purchase | 9,200 | $3.85 |
| 2025-11-24 | Hoffman Michael B | Director | Open market purchase | 415 | $4.14 |
| 2025-11-24 | Hoffman Michael B | Director | Open market purchase | 28,096 | $4.15 |
| 2025-11-21 | Hoffman Michael B | Director | Open market purchase | 10,000 | $3.49 |
| 2025-11-21 | Hoffman Michael B | Director | Open market purchase | 10,000 | $3.50 |
| 2025-11-14 | Hoffman Michael B | Director | Open market purchase | 15,000 | $2.11 |
| 2025-10-28 | Maccecchini Maria-Luisa | President & CEO | Open market purchase | 97,561 | $2.05 |
| 2025-10-28 | Hoffman Michael B | Director | Open market purchase | 975,610 | $2.05 |
| 2025-09-10 | Bruck Claudine | Director | Option exercise | 7,142 | $0.14 |
| 2025-08-29 | Hoffman Michael B | Director | Grant / award | 5,000 | $2.28 |
| 2025-08-29 | Hoffman Michael B | Director | Grant / award | 5,000 | $2.29 |
| 2025-08-29 | Hoffman Michael B | Director | Grant / award | 5,000 | $2.30 |
| 2025-08-19 | Hoffman Michael B | Director | Grant / award | 6,717 | $2.60 |
| 2025-08-19 | Hoffman Michael B | Director | Grant / award | 5,283 | $2.59 |
| 2025-08-19 | Hoffman Michael B | Director | Grant / award | 5,545 | $2.58 |
| 2025-08-19 | Hoffman Michael B | Director | Grant / award | 1,100 | $2.57 |
| 2025-06-16 | Walsh Andrew | Vice President, Finance | Grant / award | 500 | $2.90 |
| 2025-06-13 | Hoffman Michael B | Director | Grant / award | 25,000 | $2.80 |
| 2025-06-13 | Hoffman Michael B | Director | Grant / award | 1 | $2.83 |
| 2025-06-10 | McCarthy Reid | Director | Grant / award | 2,000 | $2.95 |
| 2025-06-04 | Maccecchini Maria-Luisa | President & CEO | Grant / award | 46,000 | $3.37 |
| 2025-05-29 | Hoffman Michael B | Director | Grant / award | 5,000 | $2.43 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 09:15 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-20 | 8-K | 2026-10-19 | View on SEC.gov → |
| 2026-08-14 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-14 | 8-K | 2026-08-14 | View on SEC.gov → |
| 2026-07-10 | 8-K | 2026-07-07 | View on SEC.gov → |
| 2026-06-17 | 8-K | 2026-06-17 | View on SEC.gov → |
| 2026-05-21 | 4 | 2026-05-20 | View on SEC.gov → |
| 2026-05-20 | 8-K | 2026-05-20 | View on SEC.gov → |
| 2026-05-15 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-05-15 | 8-K | 2026-05-15 | View on SEC.gov → |
| 2026-04-10 | 8-K | 2026-04-09 | View on SEC.gov → |
| 2026-04-03 | 4 | 2026-04-02 | View on SEC.gov → |
| 2026-03-25 | 8-K | 2026-03-23 | View on SEC.gov → |
Recent news
Headlines about ANVS (Annovis Bio, Inc.). Links open the publisher — we don’t host full articles.
-
ANVS 8-K & SEC Filings
Yahoo Finance · 2026-10-20 -
Annovis Bio Updates Audit Fee Details in June 2026 Proxy Statement Correction
Kalkine Media · 2026-10-20 -
ANVS261016C00002000 Interactive Stock Chart | ANVS Oct 2026 2.000 call Stock
Yahoo Finance · 2026-10-15 -
ANVS261016C00001500 Interactive Stock Chart | ANVS Oct 2026 1.500 call Stock
Yahoo Finance · 2026-10-15 -
Annovis Bio (ANVS) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Yahoo Finance · 2026-09-08 -
Annovis Bio Targets March 2027 Alzheimer’s Readout, Prepares Rolling NDA
Yahoo Finance · 2026-09-03 -
Annovis to Host Corporate Update Webinar on September 2, 2026
Yahoo Finance · 2026-08-25 -
Annovis Bio GAAP EPS of -$0.40 beats by $0.05
Seeking Alpha · 2026-08-14
No headlines in this category right now — try “All”.